ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Study: DPP4 Inhibitors Yield Promise for Systemic Sclerosis Treatment

Ruth Jessen Hickman, MD  |  November 12, 2020

A recent paper in Arthritis & Rheumatology opens up the possibility of a new research avenue to treat systemic sclerosis: dipeptidyl peptidase 4 (DPP4) inhibitors, a previously approved therapy for type 2 diabetes.1 Work in mouse models and on skin samples from systemic sclerosis patients suggests these drugs pose a promising area of future translational…

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:DPP4 inhibitorsystemic sclerosis (SSc)

What’s the Role of Epstein-Barr Virus Reactivation in Lupus Development?

Larry Beresford   |  November 12, 2020

A strong association between Epstein-Barr virus (EBV) infections and systemic lupus erythematosus (SLE) has been known since the 1970s. Although the etiology of SLE is not fully established, multiple genetic factors and polymorphisms in genes involved in the immune system have been implicated, with environmental factors also contributing to the development of this complex condition….

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Epstein-Barr virus (EBV)

The 2020 ACR Awards of Distinction & Masters Class

Linda Childers  |  November 12, 2020

Presidential Gold Medal The highest award the ACR can bestow, the Presidential Gold Medal is awarded in recognition of outstanding achievements in rheumatology over an entire career. This year’s award went to James O’Dell, MD, the Stokes-Shackleford Professor of Internal Medicine, vice chair of internal medicine and chief of the Division of Rheumatology at the…

Filed under:Awards Tagged with:ACR Convergence 2020Ciarán M. DuffyDr. Abby AbelsonDr. Ami Aalok ShahDr. Andras PerlDr. Angela TincaniDr. Bernardo A. Pons-EstelDr. Brian F. MandellDr. Carlos J. LozadaDr. Daniel SolomonDr. Edward K.L. ChanDr. Emily IsaacsDr. James O’DellDr. James R. SeiboldDr. James WitterDr. Joanne M. JordanDr. Kara PetersenDr. Kathleen M. O’NeilDr. Leonard H. SigalDr. M. Virginia PascualDr. Martin Jan BergmanDr. Michael B. BrennerDr. Nancy E. LaneDr. Norman T. IlowiteDr. Pamela WeissDr. Pierre MiossecDr. Robert W. WarrenDr. Sheldon SolomonDr. Stuart Kassan

Dr. Fauci Talks COVID-19 with the ACR

Susan Bernstein  |  November 10, 2020

ACR CONVERGENCE 2020—At the ACR’s fully virtual annual meeting on Saturday, Nov. 7, Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID) since 1984, delivered a special lecture on COVID-19, from virology to therapy to vaccine development. Novel Coronavirus, Familiar Vectors When Chinese physicians first reported infections by what…

Filed under:ACR ConvergenceMeeting Reports Tagged with:ACR Convergence 2020Anthony S. FauciCOVID-19

G-Stock Studio / shutterstock.com

Conquering Systemic Racism in Medicine

Kimberly Retzlaff  |  October 19, 2020

2020 has not only borne witness to a global pandemic, but also to increasing fervor in the fight for racial equity. In a wave of opposition to the systemic racism in the U.S., people have been in the streets demonstrating and protesting against social injustice and have taken to social media to promote political action….

Filed under:EthicsProfessional Topics Tagged with:biasraceracial disparities

Space & Other Races

Philip Seo, MD, MHS  |  October 19, 2020

On April 5, 1950, a small group of scientists met in Silver Spring, Md., to talk about geophysics. I know this is not the most riveting way to start, but if you stick with me, I promise the story will get much more interesting. This group of scientists met to discuss all that was still…

Filed under:Drug UpdatesOpinionRheuminationsSpeak Out Rheum Tagged with:COVID-19vaccines

Case Report: A 40-Year-Old Man with Vasculitic Neuropathy

Case Report: A 40-Year-Old Man with Vasculitic Neuropathy

Martin Garber, DO, & David Fivenson, MD  |  October 19, 2020

Ironically, chronic exposure to minocycline has also been associated with a variety of autoimmune syndromes, including drug-induced lupus, auto­immune hepatitis, serum sickness and vasculitis.1 Minocycline is associated with an 8.5-fold increased risk of drug-induced lupus.2 Minocycline and nitrofurantoin are implicated in 90% of cases of drug-induced autoimmune hepatitis.3 Minocycline-induced vasculitis is much less common and,…

Filed under:ConditionsVasculitis Tagged with:minocyclinepolyarteritis nodosavasculitic neuropathy

Ultrasound Provides Insights into Immune Checkpoint Inhibitor‐Induced Inflammatory Arthritis

Elizabeth Hofheinz, MPH, MEd  |  October 12, 2020

Ultrasound may provide unique insights into the effects of immune checkpoint inhibitors on the human body beyond the immune system. Research suggests synovitis and inflammatory tendon involvement are commonly seen in patients with immune checkpoint inhibitor-induced inflammatory arthritis.

Filed under:Conditions Tagged with:ACR Open RheumatologyICI‐induced inflammatory arthritisimmune checkpoint inhibitor (ICI)Immune checkpoint inhibitorsInflammatory arthritisUltrasound

Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments

Larry Beresford  |  October 7, 2020

An observational study found treatment with tofacitinib resulted in only a slightly higher rate of venous thromboembolism than tumor necrosis factor inhibitors in patients with rheumatoid arthritis.

Filed under:Drug Updates Tagged with:JAK inhibitorsjakinibRheumatoid Arthritis (RA)TNF inhibitorsTofacitinib

Sedentary Lifestyle Linked to Reduced Quality of Life in People with Knee OA

Mary Beth Nierengarten  |  September 21, 2020

Physical inactivity significantly affects disease burden and reduces the overall quality of life in patients with knee osteoarthritis (OA), according to a study from Losina et al. The researchers calculated the total quality-adjusted life-years lost for U.S. patients with OA due to inactivity.

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis Care & ResearchkneeKnee Osteoarthritis (OA)Osteoarthritis

  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 86
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences